Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

被引:102
作者
Kim, Kwan Il [1 ]
Lee, Kyung Hee [1 ]
Kim, Tae Ryung [1 ]
Chun, Yong Soon [1 ]
Lee, Tae Hoon [1 ]
Park, Heung Kyu [1 ]
机构
[1] Gachon Univ, Gil Hosp, Dept Surg, Inchon 405760, South Korea
关键词
Breast neoplasms; Ki-67; antigen; Neoadjuvant therapy; Predictive value of tests; KI67; CHEMOSENSITIVITY; INFORMATION; EXPRESSION; PROGNOSIS; MARKER; TUMORS;
D O I
10.4048/jbc.2014.17.1.40
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The objectives of this study were to assess the potential value of Ki-67 in predicting response to neoadjuvant chemotherapy in breast cancer patients and to suggest a reasonable cutoff value for classifying Ki-67 expression. Methods: This study included 74 breast cancer patients who underwent surgery after anthracycline-based neoadjuvant chemotherapy between 2007 and 2012. We analyzed the clinical and immunohistochemical characteristics using core biopsy specimens obtained before neoadjuvant chemotherapy to determine their correlations with the response to chemotherapy. Results: A clinical complete response was observed in 6 patients (8.1%); a clinical partial response, in 44 patients (59.5%); and clinical stable disease, in 24 patients (32.4%). A pathologic complete response (pCR) was observed in 10 patients (13.5%). In univariate analysis, estrogen receptor (ER) negativity (p=0.031), human epidermal growth factor receptor 2 (HER2) positivity (p=0.040), and high Ki-67 expression (p=0.036) were predictive factors for a pCR. In multivariate analysis, Ki-67 was the only independent predictor of a pCR (p=0.049). The analysis of Ki-67 values revealed that 25% was a reasonable cutoff value for predicting the response to chemotherapy. In subgroup analysis, a higher Ki-67 value (>= 5%) was a significant predictive factor for the response to neoadjuvant chemotherapy, especially in ER-negative and HER2-positive breast cancer patients. Conclusion: Ki-67 expression in breast cancer tissue may be an effective factor for predicting the response to neoadjuvant chemotherapy. We suggest that a 25% level of Ki-67 expression is a reasonable cutoff value for predicting a response to chemotherapy. Moreover, Ki-67 is a useful predictive factor for pCR, especially in patients with ER-negative and HER2-positive breast cancer.
引用
收藏
页码:40 / 46
页数:7
相关论文
共 16 条
  • [1] Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors:: A study of preoperative treatment
    Colleoni, M
    Viale, G
    Zahrieh, D
    Pruneri, G
    Gentilini, O
    Veronesi, P
    Gelber, RD
    Curigliano, G
    Torrisi, R
    Luini, A
    Intra, M
    Galimberti, V
    Renne, G
    Nolè, F
    Peruzzotti, G
    Goldhirsch, A
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (19) : 6622 - 6628
  • [2] Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
    de Azambuja, E.
    Cardoso, F.
    de Castro, G., Jr.
    Colozza, M.
    Mano, M. S.
    Durbecq, V.
    Sotiriou, C.
    Larsimont, D.
    Piccart-Gebhart, M. J.
    Paesmans, M.
    [J]. BRITISH JOURNAL OF CANCER, 2007, 96 (10) : 1504 - 1513
  • [3] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [4] Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
    Fasching, Peter A.
    Heusinger, Katharina
    Haeberle, Lothar
    Niklos, Melitta
    Hein, Alexander
    Bayer, Christian M.
    Rauh, Claudia
    Schulz-Wendtland, Ruediger
    Bani, Mayada R.
    Schrauder, Michael
    Kahmann, Laura
    Lux, Michael P.
    Strehl, Johanna D.
    Hartmann, Arndt
    Dimmler, Arno
    Beckmann, Matthias W.
    Wachter, David L.
    [J]. BMC CANCER, 2011, 11
  • [5] American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
    Harris, Lyndsay
    Fritsche, Herbert
    Mennel, Robert
    Norton, Larry
    Ravdin, Peter
    Taube, Sheila
    Somerfield, Mark R.
    Hayes, Daniel F.
    Bast, Robert C., Jr.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5287 - 5312
  • [6] Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy
    Hennessy, BT
    Hortobagyi, GN
    Rouzier, R
    Kuerer, H
    Sneige, N
    Buzdar, AU
    Kau, SW
    Fornage, B
    Sahin, A
    Broglio, K
    Singletary, SE
    Valero, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) : 9304 - 9311
  • [7] Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response
    Jones, Robin L.
    Smith, Ian E.
    [J]. LANCET ONCOLOGY, 2006, 7 (10) : 869 - 874
  • [8] Ki-67 Expression Gives Additional Prognostic Information on St. Gallen 2007 and Adjuvant! Online Risk Categories in Early Breast Cancer
    Jung, So-Youn
    Han, Wonshik
    Lee, Jong Won
    Ko, Eunyoung
    Kim, Eunkyu
    Yu, Jong-Han
    Moon, Hyeong-Gon
    Park, In Ae
    Oh, Do-Youn
    Im, Seock-Ah
    Kim, Tae-You
    Hwang, Ki-Tae
    Kim, Sung-Won
    Noh, Dong-Young
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (05) : 1112 - 1121
  • [9] Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer
    Li, Xi-ru
    Liu, Mei
    Zhang, Yan-jun
    Wang, Jian-dong
    Zheng, Yi-qiong
    Li, Jie
    Ma, Bing
    Song, Xin
    [J]. MEDICAL ONCOLOGY, 2011, 28 : S31 - S38
  • [10] Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis
    Nishimura, Reiki
    Osako, Tomofumi
    Okumura, Yasuhiro
    Hayashi, Mitsuhiro
    Arima, Nobuyuki
    [J]. BREAST CANCER, 2010, 17 (04) : 269 - 275